At its founding, ResMed had eight employees, AU$1.2 million to grow the business, and limited manufacturing capabilities. Today we operate in 100 countries, have manufacturing sites in Australia, France, Singapore and the U.S., employ more than 4,000 people and are listed on the New York and Australian stock exchanges. ResMed generated revenue of US$1.5 billion in FY 2013, has a five-year annual growth rate of 13 percent in revenue and 24 percent in net income, as well as more than $1 billion in cash.
From the beginning, we’ve been making CPAP devices quieter, more comfortable and easier to use. We invest about 8 percent of revenue in research and development, and have approximately 3,000 patents and designs.
Our core market is the treatment of sleep-disordered breathing (SDB) with an emphasis on obstructive sleep apnea (OSA). Recently we have identified respiratory care and cardiology as target areas for further growth, while we continue to lead the SDB market.